Plasma C18 :0‐ceramide is a novel potential biomarker for disease severity in myasthenia gravis
Journal of Neurochemistry · 2023
DOI: 10.1111/jnc.15837 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, 2023. Verfasst von Zhouao Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Ceramides, Myasthenia Gravis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Myasthenia gravis (MG) is an antibody‐mediated autoimmune disorder characterized by fluctuation of fatigue and weakness of muscle. Due to the heterogeneity of the course of MG, available biomarkers for prognostic prediction are urgently needed. Ceramide (Cer) was reported to participate in immune regulation and many autoimmune diseases, but its effects on MG remain undefined. This study aimed to investigate the ceramides expression levels in MG patients and their potential as novel biomarkers of disease severity. Levels of plasma ceramides were determined by ultra performance liquid chromatography–tandem mass spectrometry (UPLC‐MS/MS). Severity of disease was assessed by quantitative MG scores (QMGs), MG‐specific activities of daily living scale (MG‐ADLs) and 15‐item MG quality of Life (MG‐QOL15). The concentrations of serum interleukin‐1β (IL‐1β), IL‐6, IL‐17A, and IL‐21 were determined by enzyme‐linked immunosorbent assay (ELISA), and the proportions of circulating memory B cells and plasmablasts were detected by flow‐cytometry assay. Four plasma ceramides levels we studied were detected higher in MG patients. And three of them (C16:0‐Cer, C18:0‐Cer, and C24:0‐Cer) were positively associated with QMGs. In addition, receiver operating characteristic (ROC) analysis suggested that plasma ceramides have a good ability of differentiating MG from HCs. Importantly, only C18:0‐Cer was shown to be positively associated with the concentration of serum IL and circulating memory B cells, and the decrease in plasma C18:0‐Cer paralleled the clinical improvement of patients with MG. All together, our data suggest that ceramides may play an important role in the immunopathological mechanism of MG, and C18:0‐Cer has the potential to be a novel biomarker for disease severity in MG. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.
ORCID-Profile: Zhouao Zhang, Yong Zhang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Z., Huang, X., Du, X., Wang, Z., Wang, Y., Xu, M., Chen, X., Yao, Q., Yan, L., & Zhang, Y. (2023). Plasma C18 :0‐ceramide is a novel potential biomarker for disease severity in myasthenia gravis. Journal of Neurochemistry. https://doi.org/10.1111/jnc.15837
Vancouver
Zhang Z, Huang X, Du X, Wang Z, Wang Y, Xu M, et al. Plasma C18 :0‐ceramide is a novel potential biomarker for disease severity in myasthenia gravis. Journal of Neurochemistry. 2023. doi:10.1111/jnc.15837
BibTeX
@article{Zhang2023,
author = {Zhang, Zhouao and Huang, Xiaoyu and Du, Xue and Wang, Zhouyi and Wang, Yingying and Xu, Mingming and Chen, Xiao and Yao, Qian and Yan, Lisha and Zhang, Yong},
title = {Plasma C18 :0‐ceramide is a novel potential biomarker for disease severity in myasthenia gravis},
journal = {Journal of Neurochemistry},
year = {2023},
doi = {10.1111/jnc.15837}
}
EUVIMED